Pamela P. Palmer is Chief Medical Officer at ACELRX PHARMACEUTICALS INC (ACRX). They have made 6 open-market trades across 1 company since 2011, most recently 2024-03-03.
CIK 0001511365
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $223K since 2011, against 1 sale. Across 5 scored buys the stock is down 3.7% at ninety days, and 4.7 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 40% | 20% |
| Avg Move | -4.5% | -3.4% | -3.7% |
| Alpha | -4.4% | -3.5% | -4.7% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACRX | SELL | 2023-08-24 | 2023-08-25 | $1.13 | $19K | -18.5% | -44.9% | -36.7% |
| ACRX | BUY | 2019-02-28 | 2019-03-04 | $2.81 | $2K | -22.1% | -11.6% | -37.0% |
| ACRX | BUY | 2018-11-19 | 2018-11-19 | $3.07 | $49K | +6.3% | -23.7% | +0.0% |
| ACRX | BUY | 2018-08-06 | 2018-08-06 | $2.75 | $102K | +6.9% | +12.1% | +47.2% |
| ACRX | BUY | 2017-08-22 | 2017-08-22 | $2.95 | $30K | +8.3% | +6.7% | -28.3% |
| ACRX | BUY | 2011-06-09 | 2011-06-13 | $4.61 | $41K | -21.8% | -0.4% | -0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.